Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 9 Hyperandrogenism 4 Neoplasms 3 Inflammation 2 Heart Failure 2 Urinary Tract Infections 1 Staphylococcal Infections 1 Spasm 1 Sleep Initiation and Maintenance Disorders 1 Skin Diseases 1 Sepsis 1 Seizures 1 Schizophrenia, Treatment-Resistant 1 Schizophrenia 1 Sarcoma 1 Retinitis 1 Renal Insufficiency, Chronic 1 Rare Diseases 1 Pulmonary Arterial Hypertension 1 Pneumonia 1 Pain 1 Obesity 1 Neutropenia 1 Migraine Disorders 1 Metabolic Syndrome 1 Menorrhagia 1 Meningitis, Bacterial 1 Meningitis 1 Lymphoma 1 Leukemia, Myeloid, Acute 1

Interventions

daratumumab 2 Urination 2 Plasma Exchange 2 sodium sulfate 1 glucarpidase 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Stents 1 Spironolactone 1 Renal Replacement Therapy 1 Renal Dialysis 1 Nephrotomy 1 Nephrostomy, Percutaneous 1 Methotrexate 1 Ischemic Preconditioning 1 Hypothermia, Induced 1 Hyperthermic Intraperitoneal Chemotherapy 1 Hemodiafiltration 1 Drug Therapy 1 Cisplatin 1 Cilastatin 1 Antibiotic Prophylaxis 1 Anesthetics 1 Aminophylline 1 Acetylcysteine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Acute Kidney Injury × Spironolactone × Clear all

NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown

Neoplasms, Critical Illness, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡